no Phase II or III trials published Most common AOD-9604 side effect / Injection-site reaction (redness, swelling) Most common reported MOTS-c side effect / Transient flushing and mild GI discomfort (anecdotal, not trial-confirmed) Growth hormone axis impact / AOD-9604 does not activate the GH receptor
The guide to maintaining weight loss after tirzepatide addresses strategies for transitioning off the compound while preserving as much of the results as possible
PMC Sikiric P, et al
During this time, we optionally offer the Optimization Panel to assess your IGF-1 levels, glucose markers, inflammation, and lipid response
If you are new to subcutaneous injections and still developing confidence with syringe technique, the larger volume and cleaner measurements reduce anxiety and errors
If you are suffering from fatigue, low energy, or weight gain B12 shots would be worth considering